Kirsten White
- Virology top 0.1%
- HIV Research and Treatment 78
- Infectious Diseases top 0.2%
- HIV/AIDS drug development and treatment 80
- HIV/AIDS Research and Interventions 48
- Emergency Medicine top 0.5%
- HIV-related health complications and treatments 10
- Hepatology top 5%
- Epidemiology top 5%
- Herpesvirus Infections and Treatments 4
- Pneumocystis jirovecii pneumonia detection and treatment 3
- Cytomegalovirus and herpesvirus research 3
-
- Biochemical and Molecular Research 15
- Co-authors
- Michael D. MillerAndrew ChengEdwin DeJesusNicolas MargotErin QuirkJavier SzwarcbergAnthony MillsJoel E. Gallant
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Kirsten White
85 papers receiving 4.0k citations
Hit Papers
Peers
Comparison fields: 5 of 93
- Virology 3.1k
- Infectious Diseases 3.8k
- Emergency Medicine 761
- Hepatology 195
- Epidemiology 635
Countries citing papers authored by Kirsten White
This map shows the geographic impact of Kirsten White's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirsten White with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirsten White more than expected).
Fields of papers citing papers by Kirsten White
This network shows the impact of papers produced by Kirsten White. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirsten White. The network helps show where Kirsten White may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kirsten White, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 20 | |
| 2 | 2017 | 18 | |
| 3 | Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trialbreakdown → | 2017 | 278 |
| 4 | Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialbreakdown → | 2017 | 257 |
| 5 | 2017 | 31 | |
| 6 | 2016 | 62 | |
| 7 | 2016 | 18 | |
| 8 | 2016 | 5 | |
| 9 | 2015 | 17 | |
| 10 | 2014 | 23 | |
| 11 | 2014 | 89 | |
| 12 | 2014 | 21 | |
| 13 | 2013 | 20 | |
| 14 | 2013 | 92 | |
| 15 | 2013 | 61 | |
| 16 | 2012 | 335 | |
| 17 | 2012 | 21 | |
| 18 | 2011 | 69 | |
| 19 | 2009 | 71 | |
| 20 | 2003 | 123 |
About Kirsten White
Kirsten White is a scholar working on Virology, Infectious Diseases and Emergency Medicine, having authored 87 papers that have together received 4.1k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (80 papers), HIV Research and Treatment (78 papers), HIV/AIDS Research and Interventions (48 papers), Biochemical and Molecular Research (15 papers), HIV-related health complications and treatments (10 papers), Herpesvirus Infections and Treatments (4 papers), Pneumocystis jirovecii pneumonia detection and treatment (3 papers) and Cytomegalovirus and herpesvirus research (3 papers). The work is most often cited by research in Virology (3.1k citations), Infectious Diseases (3.8k citations) and Emergency Medicine (761 citations). Kirsten White has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Michael D. Miller, Andrew Cheng, Edwin DeJesus, Nicolas Margot, Erin Quirk, Javier Szwarcberg, Anthony Mills, Joel E. Gallant, Paul E. Sax and Xuelian Wei. Their work appears in journals such as The Lancet, Journal of Biological Chemistry and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.